Fig. 4

Suppressing TAGLN2 elevates sensitivity to chemodrugs. (A, B) Irradiation (0, 2, 4, 6, and 8 Gy) reduces the number of colonies and the surviving fractions at different doses in cells in which TAGLN2 is suppressed using shRNA (shTAGLN2-1, -2) compared to control vector-transfected cells. (C) TAGLN2 expression in gemcitabine-resistant SNU1196 (SNU1196/GR). (D) TAGLN2 expression silenced by 150 nM siRNA in 1196/GR cells for chemosensitivity analysis. (E) Silencing TAGLN2 expression enhances sensitivity to gemcitabine. (F) Combined use of TAGLN2 siRNA with chemodrugs, including 5-FU, cisplatin, oxaliplatin, and carboplatin, enhances chemosensitivity. (G) Combined use of TAGLN2 siRNA with chemodrugs, including irinotecan, etoposide, and erlotinib, has no effect on chemosensitivity. (H) Combined use of TAGLN2 siRNA with cMET inhibitor crizotinib and savolitinib enhances chemosensitivity